Journal article
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: US Preventive Services Task Force Recommendation Statement
Annals of internal medicine, Vol.164(12), pp.836-U103
06/21/2016
DOI: 10.7326/M16-0577
PMID: 27064677
Abstract
Description: Update of the 2009 USPSTF recommendation on aspirin use to prevent cardiovascular disease (CVD) events and the 2007 recommendation on aspirin and nonsteroidal anti-inflammatory drug use to prevent colorectal cancer (CRC).
Methods: The USPSTF reviewed 5 additional studies of aspirin for the primary prevention of CVD and several additional analyses of CRC follow-up data. The USPSTF also relied on commissioned systematic reviews of all-cause mortality and total cancer incidence and mortality and a comprehensive review of harms. The USPSTF then used a microsimulation model to systematically estimate the balance of benefits and harms.
Population: This recommendation applies to adults aged 40 years or older without known CVD and without increased bleeding risk.
Recommendations: The USPSTF recommends initiating low-dose aspirin use for the primary prevention of CVD and CRC in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years. (B recommendation)
The decision to initiate low-dose aspirin use for the primary prevention of CVD and CRC in adults aged 60 to 69 years who have a 10% or greater 10-year CVD risk should be an individual one. Persons who are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years are more likely to benefit. Persons who place a higher value on the potential benefits than the potential harms may choose to initiate low-dose aspirin. (C recommendation)
The current evidence is insufficient to assess the balance of benefits and harms of initiating aspirin use for the primary prevention of CVD and CRC in adults younger than 50 years. (I statement)
The current evidence is insufficient to assess the balance of benefits and harms of initiating aspirin use for the primary prevention of CVD and CRC in adults aged 70 years or older. (I statement)
Details
- Title: Subtitle
- Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: US Preventive Services Task Force Recommendation Statement
- Creators
- Kirsten Bibbins-Domingo - United States Preventive Services Task ForceUS Preventive Services Task Force
- Contributors
- Susan J Curry (Contributor) - University of Iowa, Community and Behavioral Health
- Resource Type
- Journal article
- Publication Details
- Annals of internal medicine, Vol.164(12), pp.836-U103
- Publisher
- Amer Coll Physicians
- DOI
- 10.7326/M16-0577
- PMID
- 27064677
- ISSN
- 0003-4819
- eISSN
- 1539-3704
- Number of pages
- 11
- Grant note
- Agency for Healthcare Research and Quality; United States Department of Health & Human Services; Agency for Healthcare Research & Quality
- Language
- English
- Date published
- 06/21/2016
- Academic Unit
- Health Management and Policy; Community and Behavioral Health
- Record Identifier
- 9984366282502771
Metrics
15 Record Views